[go: up one dir, main page]

WO2009010810A3 - Cardiovascular combinations comprising ace and hmg-co-a inhibitors - Google Patents

Cardiovascular combinations comprising ace and hmg-co-a inhibitors Download PDF

Info

Publication number
WO2009010810A3
WO2009010810A3 PCT/IB2006/002614 IB2006002614W WO2009010810A3 WO 2009010810 A3 WO2009010810 A3 WO 2009010810A3 IB 2006002614 W IB2006002614 W IB 2006002614W WO 2009010810 A3 WO2009010810 A3 WO 2009010810A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
hmg
cardiovascular
ace
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002614
Other languages
French (fr)
Other versions
WO2009010810A2 (en
Inventor
Eswaran Krishnan Iyer
Rasendra Kumar Jayantilal Jha
Girish Kumar Jain
Abdul Rehman Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to PCT/IB2006/002614 priority Critical patent/WO2009010810A2/en
Publication of WO2009010810A2 publication Critical patent/WO2009010810A2/en
Anticipated expiration legal-status Critical
Publication of WO2009010810A3 publication Critical patent/WO2009010810A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention describes new pharmaceutical compositions, their method of manufacture and use of these compositions to be administered as combination therapy for the treatment of cardiovascular and related disorders, in particular a combination of ACE inhibitors or Calcium channel blockers, lipid regulators (HMG-Co-A inhibitors) and platelet aggregation inhibitors.
PCT/IB2006/002614 2006-08-07 2006-08-07 Cardiovascular combinations comprising ace and hmg-co-a inhibitors Ceased WO2009010810A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/002614 WO2009010810A2 (en) 2006-08-07 2006-08-07 Cardiovascular combinations comprising ace and hmg-co-a inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/002614 WO2009010810A2 (en) 2006-08-07 2006-08-07 Cardiovascular combinations comprising ace and hmg-co-a inhibitors

Publications (2)

Publication Number Publication Date
WO2009010810A2 WO2009010810A2 (en) 2009-01-22
WO2009010810A3 true WO2009010810A3 (en) 2009-04-16

Family

ID=40260141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002614 Ceased WO2009010810A2 (en) 2006-08-07 2006-08-07 Cardiovascular combinations comprising ace and hmg-co-a inhibitors

Country Status (1)

Country Link
WO (1) WO2009010810A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
CA2755543A1 (en) * 2009-03-13 2010-09-16 Nucitec S.A. De C.V. Compositions and methods for treatment and prevention of cardiovascular disease
EP2340814A3 (en) * 2009-12-31 2012-05-23 Ranbaxy Laboratories Limited A stable aspirin tablet and process of preparation thereof
AU2011237461B2 (en) 2010-04-08 2015-11-26 The Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
WO2014167423A2 (en) 2013-03-15 2014-10-16 The Hospital For Sick Children Methods for modulating autophagy using remote ischemic conditioning
US10098779B2 (en) 2013-03-15 2018-10-16 The Hospital For Sick Children Treatment of erectile dysfunction using remote ischemic conditioning
WO2014199239A2 (en) 2013-03-15 2014-12-18 The Hospital For Sick Children Methods relating to the use of remote ischemic conditioning
WO2018200691A2 (en) 2017-04-25 2018-11-01 Proteus Digital Health, Inc. Lisinopril compositions with an ingestible event marker
CN108464972A (en) * 2018-07-02 2018-08-31 福州大学 A kind of anti-pulmonary hypertension oral tablet and preparation method thereof containing Snopori
CN113081996A (en) * 2021-04-01 2021-07-09 海南锦瑞制药有限公司 Simvastatin capsule and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022890A1 (en) * 1999-12-06 2003-01-30 Atwal Karnail S. Heterocyclic dihydropyrimidine compounds
US20040022844A1 (en) * 2001-10-30 2004-02-05 Steffen Hasenzahl Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040110793A1 (en) * 2002-04-19 2004-06-10 John Lloyd Heterocyclo inhibitors of potassium channel function

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022890A1 (en) * 1999-12-06 2003-01-30 Atwal Karnail S. Heterocyclic dihydropyrimidine compounds
US20040022844A1 (en) * 2001-10-30 2004-02-05 Steffen Hasenzahl Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040110793A1 (en) * 2002-04-19 2004-06-10 John Lloyd Heterocyclo inhibitors of potassium channel function

Also Published As

Publication number Publication date
WO2009010810A2 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
WO2008115974A3 (en) Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2012080727A3 (en) Casein kinase 1delta (ck1delta) inhibitors
EP2129683A4 (en) Methods and compositions for the treatment of heart failure and other disorders
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
MY150285A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
WO2012154679A8 (en) Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
WO2007143607A3 (en) Method of treating atrophic vaginitis
WO2009121872A3 (en) Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2012135619A3 (en) Intranasal benzodiazepine pharmaceutical compositions
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
MX2009004017A (en) The uses of the carboxy-amido-triazole compounds and salts thereof.
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06795533

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06795533

Country of ref document: EP

Kind code of ref document: A2